Synthetic cannabinoids are one of the most significant groups within the category new psychoactive substances (NPS) and in recent years new compounds have continuously been introduced to the market of recreational drugs. A sensitive and quantitative screening method in urine with metabolites of frequently seized compounds in Norway (AB-FUBINACA, AB-PINACA, AB-CHMINACA, AM-2201, AKB48, 5F-AKB48, BB-22, JWH-018, JWH-073, JWH-081, JWH-122, JWH-203, JWH-250, PB-22, 5F-PB-22, RCS-4, THJ-2201, and UR-144) using ultra-high pressure liquid chromatography-quadrupole time of flight-mass spectrometry (UHPLC-QTOF-MS) has been developed. The samples were treated with ß-glucuronidase prior to extraction and solid-phase extraction was used. Liquid handling was automated using a robot.
pentyl-1H-indol-3-yl)methanone] was identified. 2 Since then, legislation has evolved to criminalize the trafficking and use of this class of compounds in many countries. At the same time, though, these legislative activities have acted as a motive to produce new compounds not covered by the current legislations. In the last decade, this "race"
has resulted in an increasing number of new SCs entering the market for recreational drugs. As one of the most important classes of new drugs, the ability to find and determine SCs in biological samples is important on an individual level (abuse, toxicity, law enforcement) as well as a social level (drug market trends, extent of trafficking).
Urinary screening methods of SCs based on immuno assay or chromatography with mass spectrometry (MS) detection, in particular liquid chromatography (LC) with quadrupole tandem-MS (MS/MS) detection, have dominated in the toxicological laboratories. 3 Used for analyses of a definite number of compounds, these techniques are a good choice due to their robustness, sensitivity, and selectivity.
However, these methods can only identify the compounds they are designed for, and updates are not easily performed. A number of quantitative screening methods in urine by LC-MS/MS have previously been published. [4] [5] [6] [7] [8] High resolution mass spectrometry (HRMS) with quadrupole time of flight (QTOF) instrumentation that acquires full spectrum data is not limited by scan/dwell times, and introducing new masses/formulas to the method will not affect the detection of the previously included ones. In addition, retrospective analysis of previously acquired data can be performed. Few articles have previously been published exploring quantitative screening of SCs using HRMS, although the technique has more frequently been used solely for qualitative targeted and non-targeted methods. [9] [10] [11] In a non-targeted method, ideally all MS spectra plus additional MS/MS spectra are acquired for a tentative identification, and can be obtained from findings of interest after sample acquisition. The method presented in this article can be described as a dynamic quantitative and targeted screening method since MS data from the first injection are used for quantification purposes while MS/MS data for confirmation are acquired in a second injection only for confirmation of a definite panel of analytes. By this approach the targets included in the method can be adjusted in accordance to the current drugs of interest. Potential disadvantages using HRMS instrumentation are the higher cost compared to LC-MS/MS and the large size of data files generated. In addition, an efficient processing of the data requires powerful computers.
In comparison with blood, advantages of detecting metabolites of drugs of abuse in urine include the expanded detection window and the non-invasive sampling. Quantification of metabolites can be valuable when a recent intake needs to be distinguished from residual drug excretion from a former intake. This principle is well known after intake of cannabis, and various algorithms have been developed for this purpose. [12] [13] [14] For synthetic cannabinoids some data exist on the urinary pharmacokinetics and excretion rate of the metabolites of JWH-018 and JWH-073, 6, 15 whereas for other compounds, very little is known. Thus, for synthetic cannabinoids more data are needed before a recent intake can be unequivocally distinguished from residual drug excretion. Nevertheless, gathering data from quantitative analyses of the various metabolites in serial urinary samples is a prerequisite for developing the algorithms needed. Moreover, the access of quantitative methods is crucial in order to carry out pharmacokinetic studies (ie, to estimate half-lives, peak concentrations and detection times in urine). However, the low concentrations of unconjugated metabolites in urine often require cleavage of the glucuronidated metabolites by hydrolysis before analysis. In previously published identification and quantification assays, preparation techniques varying from simple dilution, 6 salting-out liquid-liquid extraction (LLE) 10 and traditional LLE 4 to more complex procedures including supported liquid extraction 9 and solid-phase extraction (SPE) 5 have been used. To simplify sample preparation, automatization of this procedure has become more common. 5, 6, 10 All SCs undergo metabolism to a certain extent. 16 Consequently, a screening method for SCs in urine must cover the most abundant and unique metabolites if an accurate determination of the drug taken is necessary. Some SCs that are biotransformed to metabolites which are unique and unambiguously can point out the specific drug ingested. However, compounds with close structural similarities often result in several identical metabolites, but in many cases also unique secondary metabolites are produced. One such example is AM-2201
and JWH-018, both having the major metabolites JWH-018 Npentanoic acid and JWH-018 N- (5-hydroxypentyl) . Nevertheless, the specific markers AM-2201 N-(4-hydroxypentyl) and AM-2201 N- (6- hydroxyindole) of AM-2201 and JWH-018 N-(4-hydroxypentyl) of JWH-018 are also formed and can be used to distinguish between intake of these two. 17, 18 A careful selection of metabolites is therefore required. New SCs that are biotransformed to metabolites identical to a drug that already is covered by a method are frequently introduced.
Consequently, the exact intake cannot be confirmed without updating the method with new available unique markers. The introduction of AMB-FUBINACA which gives the same metabolite as AB-FUBINACA is an example of the latter. 19 Reference standards are necessary for performing quantification. It is both a time-consuming and a resource-demanding process from the time a new drug is introduced on the market to the point when selected metabolites have been synthesized and can be included in a new or updated method. Potential metabolites can be identified by exposing human liver microsomes 20, 21 or human hepatocytes 22 to the drug in question, and analyze the residues with MS, together with urinary samples from people with known consumption of the same drug.
The aim of the present study was to develop a high throughput quantitative screening method for SCs in urine, using LC-QTOF-MS and automated sample preparation. To evaluate the feasibility of the method in clinical practice, we also aimed to describe our experience and results from analyzing a total of 1000 consecutive routine urinary samples sent to our laboratory where screening for SCs had been requested.
| MATERIALS AND METHODS
The analytes included in this method consisted of commercially available and assumed relevant metabolites of the SCs most frequently used in Norway at the time the method was developed. The seizure statistics from the Norwegian National Criminal Investigation Service (KRIPOS) were used to choose relevant SCs. A complete list of the metabolites included, formulas, monoisotopic masses, CAS numbers, IUPAC names, and structures is given in the Supporting Information (Table S1 ). 
| Chemicals and reagents

| Preparation of solutions
Stock solutions of the reference compounds were prepared and further diluted and combined into five different working solutions. One set was prepared for calibrators and one set for quality controls (QCs). Calibrators and QCs were prepared by fortifying blank urine with the working solutions and stored at 4°C. An overview of the calibration levels, QCs, and distribution of metabolites in working solutions are given in the Supporting Information (Table S2) 
| Authentic samples
The method was applied on a total of 1000 consecutive routine urinary samples sent to our laboratory for which screening for SCs had been requested. These samples originated from subjects in whom an intake of SCs was suspected, mainly patients enrolled in medication-assisted treatment programs for drug dependence and patients undergoing other forms of treatment for drug dependence. The samples were received from all over Norway and were collected through 2014 and in the first half of January 2015. At arrival at the laboratory, these samples were principally analyzed with a routine targeted LC-MS/ 
| Method optimization
The method optimization aimed at developing a general method that could detect the relatively diverse group of metabolites and also 
| Sample preparation
All pipetting operations were performed using aTecan Freedom Evo pipetting robot (Tecan, Männedorf, Switzerland). Urine sample, calibrator, or QC in aliquots of 600 μL was pipetted into a 2-mL 96-well plate. Volumes of 20 μL internal standard solution, 600 μL ammonium acetate and 25 μL β-glucuronidase were added and the plate was incubated for 1 h at 60°C.
After cooling to ambient temperature, 1000 μL of the sample was trans- 
| Instrumentation
Instrumental analysis was performed using a 6550 QTOF-MS (Agilent, Santa Clara, CA, USA) with electrospray ionization (ESI) and iFunnel interface coupled with a 1290 Infinity UHPLC system from Agilent.
Mobile phase A and B consisted of 0.1% formic acid in water and acetonitrile, respectively, and separation was achieved using a Zorbax Eclipse Plus C18 Rapid Resolution HD column (2.1x100 mm, 1.8 μm)
from Agilent maintained at 60°C. A linear gradient with a flow of 0.30 mL/min starting at 10% mobile phase B increasing to 50% in 2 minutes, continuing to 60% in the next 6 minutes and further increasing to 95% in 1 minute was employed. This condition was maintained for 3 minutes and before the next injection the initial condition was held for 2 minutes, giving a total cycle time of 14 minutes.
Positive ionization was used with the fragmentor voltage at 375 V, capillary voltage at 3500 V, gas temperature at 150°C, gas flow 
| Library spectra
CID spectra were added to the in-house library according to Broecker et al. 23 This procedure involved diluting individual 1 mg/mL stock solutions of SCs in methanol to 100 ng/mL and then 1 μL was injected on a guard column with 0.1% formic acid in water and 0.1% formic acid in acetonitrile (50:50) as mobile phase. Three CID spectra of the protonated compound using collision energies of 10, 20, and 40 eV were acquired.
The acquired CID spectra were transferred to the library file using
MassHunter Qualitative software (Qual) B.07.01 and MassHunter PCDL Manager B.07.01 (Agilent). In this process the fragment masses in every spectrum were corrected to their theoretical masses.
Fragments with intensities lower than 1% of the most abundant mass in each spectrum were deleted.
| Quantification and confirmation of compounds
Quantification and confirmation of the compounds was done by two injections where the first was using MS-only and the second was using by the software were manually reviewed and a sample was presumed positive if above the limit of quantification (LOQ) as defined in Section 2.9.1 and additionally gave a mass match score ≥ 80 in Qual software, using profile data and "Find by Formula" (ID criterion II). This score was based on accurate mass and isotopic pattern from a database of the analytes, and only the compounds with a mass error of ±15 parts per million (ppm) and a deviation of ±0.15 minutes from the RT given in the database were considered. The mass match score was calculated using the following equation:
The accuracy was weighted (w) 100, abundance was weighted 80 and isotope spacing was weighted 50.
A threshold mass match score of 80 out of 100 was chosen based on experience through method development and gave only a few presumable positive findings that were not confirmed.
In case of presumable positive findings, the MS/MS spectra acquired in a second injection were compared with a spectral library holding reference CID spectra for all the compounds in the target list Figure S1 . The minimum concentration in spiked negative samples which fulfilled this most stringent criterion was defined as the limit of confirmation (LOC).
This approach may result in a quantitative finding in the first assumption but the sample ending up negative after the second injection if the LOC was higher.
| Method validation
LOQ, linearity, selectivity, RT stability, carry-over, matrix effects, recovery, precision, accuracy, and stability are parameters recommended to evaluate during method validation for forensic applications. 24 All these parameters were included in the validation and the number of calibration levels, parallels and analytical runs as well as acceptance limits are described in the following paragraphs.
| Limit of quantification and limit of confirmation
LOQ was first evaluated for each analyte by spiking blank urine to different concentration levels (0.01-5 ng/mL). The lowest concentration level giving reproducible results when analyzed at 10 days with precision (CV) < 20% and accuracy within 80%-120% of the theoretical value was defined as LOQ.
LOC was defined as the lowest concentration identified by the library search identification criteria (ID criterion III). A serial dilution of spiked urine was first analyzed to estimate this limit. Blank urine from different individuals was then spiked at three or four concentration levels equal to and around the estimated LOC (in the range of 0.01-5 ng/mL). The concentration level where the compound was identified in all urines using criterion III was set to the LOC.
| Linearity
The linear range of every compound was explored by using the analyzed calibrators from the first four days of validation (all days within a week) at six calibration levels (except AB-PINACA pentanoic acid, AB-CHMINACA M1A, and RCS-4 N-(4-hydroxypentyl)phenol where five levels were used) in a linear least square regression employing 1/x or 1/x 2 weighting and reported as the correlation coefficient R 2 .
The concentration range was defined from LOQ to highest calibration concentration. R 2 ≥ 0.990 was regarded as accepted.
| Selectivity
The selectivity of the method was evaluated by spiking 10 different 
| Retention time stability
The stability of RT and relative RT (ratio of analyte RT to internal standard RT) was monitored through an analytical sequence of minimum 14 hours at three random validation days. The deviation of RT and relative RT in QC samples through the sequence to the average RT of the calibrators in the beginning of the run was calculated. RT deviation ≤1% throughout an analytical sequence up to 14 hours was accepted.
| Carry-over in the LC system
The carry-over from a high concentration sample to the next was determined by injecting blank urine after a sample containing a concentration equal to its highest calibration level or at least 125 ng/mL. A carry-over <20% of LOQ was accepted.
| Matrix effects
To estimate the matrix effect (ME) reconstitution reagent (A) (80/20 mobile phase A/B (v/v)) and 10 extracted blank urines (B) was fortified with all compounds and analyzed to acquire the analyte signal. ME (%) 
as acceptable for quantification of compounds lacking a dedicated isotopically marked internal standard.
| Recovery
The extraction efficiency was estimated by comparing the signal in six blank urines fortified with all compounds after extraction (B) to the signal in the same samples fortified to the identical concentration level before extraction (C). Internal standards were added in the same amount to all samples after extraction. Recovery was calculated as
[area of compound relative to internal standard in C/area of compound relative to internal standard in B] x 100%. Recoveries ≥75%
were regarded as acceptable for quantification.
| Precision and accuracy
The intra-day precision was determined by analyzing 10 parallels of two concentration levels in the same sequence. The inter-day precision was calculated by analyzing one sample at two different concentration levels at 10 different days over a period of five weeks.
The acceptance criterion of intra-and inter-sequence precision at both concentration levels was a CV ≤ 15%. The average value of the inter-day data was used to calculate the accuracy expressed as the deviation from theoretical/nominal value. The acceptance criterion of accuracy was values in the interval 85%-115%.
| Stability
The stability of the compounds was tested at different temperature conditions in spiked QC samples stored in glass tubes at one concentration level. Spiked QC samples were stored in darkness at 4°C to simulate the standard storage conditions from receiving a sample to its analysis. QC samples were analyzed after seven and 14 days. In addition QC samples were stored for three and five days at 25°C in darkness to simulate typical conditions during transport from the sampling location to the laboratory. Stored samples at 4°C and 25°C were analyzed together with freshly thawed samples and relative changes in concentration were reported. In addition the stability of extracted samples in the autosampler at 10°C was re-tested at three and seven
days. An interval of three days covers the maximum time that can be experienced between first and second injection as there can be a delay between the first injection via processing and the second injection.
The seven-day period was included to explore the time frame for a typical postponement due to e.g. instrument failure.
| RESULTS
A quantitative UHPLC-QTOF-MS screening method of 35 SC metabolites with a run time of 14 minutes was achieved. A second injection with the same run time was required for confirmation by acquiring MS/MS-spectra for library search.
| Method validation
The validation parameters were within the set criteria and requirements for the majority of analytes. However, high matrix effects and insufficient recoveries question the ability to accurately quantify 14 of the investigated analytes and therefore the method must consider being semi-quantitative for these compounds (Table 1) .
| Chromatographic separation
Ideally the LC set-up should manage to separate all compounds with identical masses and similar MS/MS spectra. The chromatogram of calibrator 2 containing all metabolites included in the method is displayed in Figure 1 . As can be observed, several compounds elute in clusters, but these co-eluting compounds are not isomers of each other and were separated based on their masses.
The first and is a more specific marker of PB-22 intake was kept, whereas PB-22 N-(5-hydroxypentyl) was excluded from the calibrators. Thus, the calibration was done based on peak height. As baseline separation was not achieved this must be regarded as semi-quantification.
| Limit of quantification and limit of confirmation
The lowest concentrations detected using the different ID criteria are given in the Supporting Information (Table S3 ). The LOQs and
LOCs of the metabolites are summarized in Table 1 . AB-PINACA pentanoic acid could not be confirmed by the library search at any of the levels explored. BB-22 3-carboxyindole could not be confirmed at the level of 17.5 ng/mL due to poor fragmentation and interferences in the MS/MS spectra. However, the metabolite AB-PINACA-COOH which showed an LOC of 2 ng/mL could be used as an alternative indicator for an intake of AB-PINACA, although this is also a metabolite of AMB. 
| Carry-over in LC system
No carry-over above 20% of LOQ after injecting a sample containing 125 ng/mL or the highest calibration level of AB-PINACA pentanoic acid (320 ng/mL), AB-CHMINACA M1A (320 ng/mL), RCS-4 N-(4-hydroxypentyl)phenol (160 ng/mL), and AB-FUBINACA M2
(240 ng/mL). This was achieved using a needle wash of eight seconds between sample draw and injection.
| Precision and accuracy
Precision expressed as relative standard deviation (%) and accuracy data expressed as bias (%) are given in Tables 1 and 2 , respectively. The acceptance criterion of intra-sequence precision (≤ 15%) at both concentration levels was achieved for all analytes.
The acceptance criterion of inter-sequence precision (≤ 15%) was 
| Matrix effects and recovery
MEs from 57% to 262% were observed ( Table 2 ). In general, the com- to calculate an ME value. 
Recovery was above the accepted limit of 75% for all compounds except JWH-210 N-(5-hydroxyindole) (10%) and JWH-210 N-(5-
hydroxypentyl) (51%) at both concentration levels ( Table 2) .
| Stability
Concentrations 
| Results of authentic samples
One or more metabolites were quantified and confirmed in 21 of the total of 1000 samples and in two additional samples metabolites There are limited data available on the expected concentrations of the different metabolites in urine after recreational use, but a relatively broad range of concentration levels, from under one and up to hundreds of ng/mL, has been reported. 5, 7, 26 The majority of the analytes have an LOC at 1 ng/mL or below which will be sufficient to confirm them at their presumable levels in urine. The window of detection will obviously be narrower if the LOC is higher. LOC of AB-PINACA pentanoic acid, RCS-4 N-(4-hydroxypentyl)phenol, RCS-4-N-pentanoic acid, AB-FUBINACA M2, PB-22 3-carboxyindole, and BB-22 3-carboxyindole was up to 50 times higher compared to LOQs presented using LC-MS/MS based methods. 4, 6, 7, 26, 27 The majority of these elute early (RTs < 4 minutes) and are more prone to ME as they co-elute The majority of compounds showed MEs and recoveries within the acceptance criteria. A general sample preparation, which was chosen here, can be used for extraction of analytes with a broad spectrum of physico-chemical properties, but a high ME and thereby unfavorable influence on the analytical quality was observed for some com- 
| Authentic samples
In the 1000 authentic samples analyzed, a total of 10 different metabolites were confirmed or identified with ID criterion II. The majority of the chosen metabolites in the method can be produced by more than one drug ( Table 1) ously been published by our group. 6 In that study, elimination half-lives of these compounds were determined and detection times established based on the LOQs of that method. 6 The relatively high LOCs of JWH-073 N-pentanoic acid and JWH-018 N-pentanoic acid in the present study as compared to the LOQ of the LC-MS/MS method, which was 0.1 ng/mL, will result in detection times of days instead of weeks.
The pentanoic acid metabolite of AKB48 was detected in six samples. The specific metabolite of 5F-AKB48 hydroxylated at the pentyl chain (5F-AKB48-N-(4-hydroxypentyl)) was not detected in any of the samples suggesting that our findings originated from AKB48 and not the 5-fluoro analogue. However, the seizure statistics from KRIPOS indicate that the use of 5F-AKB48 was more frequent than AKB48
at the time of sample collection. Previous studies have showed that both AKB48 and 5F-AKB48 are metabolized to AKB-48 N-pentanoic acid and AKB48-N-(5-hydroxypentyl). 21, 36 Our initial findings could therefore not unambiguously determine which compounds were taken by these individuals.
A retrospective search for the general formula of hydroxylated 5F-AKB48 (C 23 H 30 FN 3 O 2 ) revealed a peak three minutes earlier than 5F-AKB48-N-(4-hydroxypentyl) in five out of the six positive samples.
By acquiring CID spectra of this compound the fragmentation pattern could be compared with the literature 21, 36 and reveal the structure In five of the six samples containing AB-FUBINACA M3 at least one metabolite of 5F-AKB48 was also detected. This can be a result of concomitant intake of either AB-FUBINACA, AMB-FUBINACA or EMB-FUBINACA and 5F-AKB48 from two different products, but it can also be caused by intake of a product containing both drugs either sold as a mix or the one being a contamination of the other. Information from KRIPOS shows that in only one out of 11 AB-FUBINACA seizures 5F-AKB48 was detected in the same product. In two out of 11 seizures of AB-FUBINACA a seizure of 5F-AKB48 was made in the same case. As our samples were anonymized before analysis we could not determine if some of them were from the same individual(s)
or from the same geographical area. A corresponding situation was seen with JWH-073, which was always detected when any of the metabolites of JWH-018 were present. A demethylation of JWH-018 to JWH-073 and further oxidation to JWH-073-N pentanoic acid has previously been hypothesized and cannot be ruled out. 5F-PB-22 3-carboxyindole could not be confirmed with spectral library in the two samples where a concentration below the LOC (< 5 ng/mL) was observed. The second injection, however, provided MS spectra that strongly indicated the presence of the compound at a concentration > 2.5 ng/mL even though the concentration was too low to be confirmed with ID criteria III. Neither 5F-PB-22 3-carboxyindole nor BB-22 3-carboxyindole are specific markers of 5F-PB or BB-22 intake, respectively. 5F-PB-22 3-carboxyindole can origin from 5F-MDMB-PICA 38 and a biotransformation of MDMB-CHMICA to BB-22 3-carboxyindole can take place. 39 Other specific markers were not available as certified reference materials. In the case of BB-22, the absence of specific metabolites for MDMB-CHMICA and AMB-CHMICA in biological samples must be documented to prove intake of this substance. 40 In statistics provided by KRIPOS of seizures in Norway in 2014, 5F-AKB48 was at the top with 43 seizures followed by 5F-PB-22, 
